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COMPARISON OF FLT3 INHIBITORS WITH THE STANDARD TREATMENT 
FOR FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA 
STEPHANIE ARGETSINGER 
ABSTRACT 
 
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, which 
is characterized by impaired differentiation and uncontrollable proliferation of myeloid 
progenitor cells in the bone marrow. One-third of patients with AML have a mutation in 
the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 mutation most commonly occurs 
as an internal tandem duplication (ITD) and is associated with a poor prognosis. Patients 
with FLT3-ITD mutated AML are able to achieve complete remission at the same rate as 
patients with wild-type FLT3 but face a higher relapse rate and reduced overall survival. 
The standard treatment for FLT3-ITD mutated AML has been intensive 
chemotherapy with or without hematopoietic stem cell transplantation (HSCT). In recent 
years, there has been an emergence of various targeted first and second generation FLT3 
inhibitors. The first-generation inhibitors lack specificity for FLT3 and include sunitinib, 
sorafenib, lestaurtinib and midostaurin. The second-generation inhibitors potently target 
FLT3 and include quizartinib, crenolanib and gilteritinib. Currently, midostaurin is the 
only FLT3 inhibitor that has been approved by the FDA to treat patients with AML. 
A barrier in AML treatment is drug resistance, which can lead to either a lack of 
efficacy or loss of prior efficacy. There are a variety of intrinsic and extrinsic 
mechanisms that underlie the acquisition of resistance. This literature review will explore 
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the clinical implications and limitations of the treatment options for patients with FLT3-
ITD mutated AML and discuss the negative impact that resistance has on efficacy. 
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INTRODUCTION 
 
 AML is an aggressive and frequently fatal hematologic malignancy that occurs in 
the bone marrow and leads to an accumulation of myeloblasts (Kumar, Abbas & Aster, 
2012). AML is the most common type of acute leukemia in adults and accounts for 1.2% 
of cancer deaths in the United States. The median age at diagnosis is 67 and the incidence 
of AML increases with age (Wander, Levis & Fathi, 2014). The prognosis for patients 
with AML varies based on multiple factors including age, cytogenetic and molecular 
features and chromosomal aberrations. The five-year survival rate for patients under 60 
years old is 40% and is 15% for patients older than 60 years old (Grunwald & Levis, 
2013). 
 One of the most common mutations detected in patients with AML occurs in the 
FLT3 gene, which encodes a type III receptor tyrosine kinase that regulates growth and 
differentiation of hematopoietic cells. The incidence of FLT3 mutations in AML patients 
is 30%, 27% occur as an ITD in the juxtamembrane domain and 7% occur as a point 
mutation in the tyrosine kinase domain (Gallogly, Lazarus & Cooper, 2017). The 
mutations lead to constitutive activation of the FLT3 receptor and its downstream 
signaling pathways, which promotes cell growth and proliferation. Patients with FLT3-
ITD mutated AML are able to achieve complete remission at the same rate as those with 
wild-type FLT3 but face a much higher relapse rate and reduced overall survival 
(Wander, Levis & Fathi, 2014). 
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 Due to the heterogeneity of AML, there are a variety of treatment options 
available. The standard treatment for AML has been intensive chemotherapy with or 
without HSCT. Since mutations in the FLT3 receptor play a crucial role in the 
pathogenesis of AML, various tyrosine kinase inhibitors have been developed to target 
FLT3 receptor tyrosine kinase signaling. These treatments include sunitinib, sorafenib, 
lestaurtinib, quizartinib, crenolanib, gilteritinib and midostaurin. Midostaurin is the first 
and only FLT3 inhibitor to be approved by the FDA thus far. An important barrier in the 
treatment of AML is drug resistance, which can lead to either a lack of efficacy or a loss 
of prior efficacy (Grunwald & Levis, 2013). 
This thesis will first provide information on the pathogenesis of AML. The next 
part of the thesis will explore the efficacy of the treatment options for patients with 
FLT3-ITD mutated AML. Finally, the thesis will discuss the mechanisms and impact of 
drug resistance in the treatment of AML. 
 
A Review of Cancer Biology 
  Cancer is the second leading cause of death in the United States (Nichols, 2017). 
There are multiple factors that contribute to the initiation and progression of cancer, 
including external influences from the environment such as tobacco, chemicals and 
radiation, as well as internal influences from within the cell such as inherited mutations, 
hormones and immune conditions (Hejmadi, 2010). Cancer can occur in any part of the 
body and there are ten hallmarks that underlie the transformation of normal cells into 
cancer cells. The ten hallmarks of cancer include sustaining proliferative signaling, 
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evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, metastasis, genome instability and mutation, tumor-promoting 
inflammation, reprogramming of metabolic pathways and ability to evade the immune 
system (Hanahan & Weinberg, 2011).  
Cells are able to maintain homeostasis by regulating growth through activation 
and deactivation of proliferative signals in the cell cycle. The cell cycle occurs in four 
stages, G1, S, G2 and M. In the G1 phase, a cell grows and carries out regular cellular 
functions. In the S phase, the cell replicates its DNA. In the G2 phase, the cell continues 
to grow to prepare for cell division. In the M phase, the cell undergoes mitosis and 
divides itself into two genetically identical daughter cells (Kumar, Abbas & Aster, 2012). 
Proto-oncogenes code for proteins that stimulate cell cycle division. The mutated version 
of a proto-oncogene is an oncogene, which exhibits increased production of the proteins 
leading to increased cell division, decreased cell differentiation and inhibition of cell 
death, leading to cancer (Chial, 2008). Tumor suppressor genes encode proteins that slow 
down cell division and mutations can prevent them from working properly (Hejmadi, 
2010). Growth suppressors are present at the checkpoint between the G1 and S phase of 
the cell cycle, which can send cells back to the G0 phase, where cells exist in a quiescent 
stage, in order to inhibit proliferation. Cancer cells are able to evade growth suppressors 
(Hanahan & Weinberg, 2011). 
Cancer cells are able to survive and proliferate by avoiding cell death and 
enabling replicative immortality. Apoptosis is programmed cell death, which occurs in 
normal cells in response to DNA damage or other types of cellular stress. Cancer cells are 
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less sensitive to the stresses that cause apoptosis and are able to resist cell death 
(Genentech, 2013). In order to enable replicative immortality, cancer cells overcome the 
finite replicative ability that normal cells have by overexpressing telomerase. In normal 
cells, telomeres shorten progressively with every division and eventually lose the ability 
to protect the ends of chromosomes. Telomerase is an enzyme that maintains telomere 
length, which protects the end of chromosomes, and this allows the cell to continue 
proliferating (Hanahan & Weinberg, 2011). 
Angiogenesis is the formation of new blood vessels, which is present in both solid 
and liquid tumors. Cancer cells can stimulate neoangiogenesis, leading to the formation 
of new vessels either from previously existing capillaries or via vasculogenesis, which is 
when endothelial cells are recruited from the bone marrow (Hanahan & Weinberg, 2011). 
The new vessels provide a supply of oxygen and nutrients, enabling cancer cells to 
continue to proliferate and allows metastasis. Metastasis is the ability of the cancer to 
spread to other parts of the body from the initial site (Genentech, 2013).  
Genome instability and mutation serve as the foundation for oncogenic processes. 
Normal cells are able to repair DNA damage but they are not able to fix everything. 
Every time the genome is replicated there is an accumulation of mutations, known as the 
basal mutation rate, which is why older people get cancer more frequently (Dolgin, 
2009). Cancer cells increase the rate of mutations by inactivating or suppressing caretaker 
genes. Caretaker genes are able to detect DNA damage and either inactivate or intercept 
mutagenic molecules or activate repair machinery (Genentech, 2013).  
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Inflammation is normally a protective response in the body but tumor-promoting 
inflammation can increase malignancy (Kumar, Abbas & Aster, 2012). This process may 
aid in malignancy by increasing the number of growth factors, pro-angiogenic factor and 
survival factors present in the tumor microenvironment or can lead to additional genetic 
mutations. The immune system is programmed to recognize and eliminate diseased cells 
but cancer cells have the ability to evade the immune system. The mechanism by which 
cancer cells are able to escape the immune system is not clear but several options have 
been proposed such as immunosuppression or antigen masking (Hanahan & Weinberg, 
2011). 
Energy metabolism is the process of generating ATP from nutrients in order to 
maintain growth and proliferation. Cellular respiration starts with glycolysis, where 
glucose undergoes a series of chemical transformations and is eventually converted into 
two molecules of pyruvate. Then pyruvate is oxidized to carbon dioxide (CO2) via the 
citric acid cycle, which also produces two electron carriers, nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) Through a series of 
redox reactions, NADH and FADH2 enter the electron transport chain to produce ATP, 
with oxygen as the final electron acceptor (Vander Heiden, Cantley & Thomson, 2009). 
Cancer cells reprogram energy metabolism in order to sustain uncontrolled proliferation 
(Genentech, 2013). One of the ways that cancer cells reprogram metabolism is by 
adjusting glucose metabolism. Even in the presence of oxygen, cancer cells convert 
pyruvate into lactate. Although this does decrease the amount of ATP that is produced, it 
allows glycolic intermediates to enter other pathways that lead to the assembly of new 
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cells and acceleration of cell proliferation (Genentech, 2013). This is known as the 
Warburg effect (Figure 1). 
 
Figure 1. Warburg Effect. Schematic representation of the differences between 
oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis (Warburg effect). 
When oxygen is limiting, cells can redirect the pyruvate generated by glycolysis away 
from mitochondrial oxidative phosphorylation by generating lactate (anaerobic 
glycolysis). This generation of lactate during anaerobic glycolysis allows glycolysis to 
continue (by cycling NADH back to NAD+), but results in minimal ATP production 
when compared with oxidative phosphorylation. Warburg observed that cancer cells tend 
to convert most glucose to lactate regardless of whether oxygen is present (aerobic 
glycolysis). Taken from (Vander Heiden, Cantley & Thomson, 2009). 
 
Pathology 
AML is a heterogeneous disease characterized by disrupted hematopoiesis in the bone 
marrow. AML develops due to genetic changes in hematopoietic progenitor cells leading 
to the malignant transformation and accumulation of myeloblasts, which replace normal 
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bone marrow cells (Ye et. al., 2015). Since the malignant cells are located in the bone 
marrow, no compact structured tumor is formed but leukemia is classified as a liquid 
tumor (Najafabadi, Shamsasenjan & Akbarzadehalaleh, 2017).  
Hematopoiesis is the process where blood cells are formed from multipotential 
hematopoietic stem cells and takes place in the bone marrow. The vasculature in the bone 
marrow forms a sinusoidal network that consists of a single layer of endothelial cells, 
which have been found to secrete several hematopoietic cytokines and supports the 
proliferation and differentiation of hematopoietic cells (Najafabadi, Shamsasenjan & 
Akbarzadehalaleh, 2017). Hematopoiesis is highly regulated and modulated by 
transcription factors and cytokine-induced stimulation of multiple signaling pathways, 
which ensures that progenitor cells appropriately differentiate and proliferate (Meshinchi 
& Appelbaum, 2009).  
The hematopoietic stem cell gives rise to two different lineages, the myeloid pathway 
and the lymphoid pathway. The lymphoid pathway differentiates into lymphocytes, a 
type of white blood cell that is part of the immune system. There are two classes of 
lymphocytes, T lymphocytes and B lymphocytes, which are involved in different aspects 
of the adaptive immune response (Kumar, Abbas & Aster, 2012). The myeloid pathway 
forms platelets, red blood cells and all white blood cells, except lymphocytes (Figure 2). 
Platelets are small fragments of cells that help with blood clotting. Red blood cells carry 
oxygen from the lungs to the rest of the body and transport CO2 back to the lungs to be 
exhaled. The white blood cells that arise from myeloid progenitor cells are neutrophils, 
eosinophils, basophils and monocytes. Neutrophils are the most common white blood cell 
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in the body and are a component of the innate immune system. Eosinophils are involved 
in inflammatory processes and allergic responses. Basophils are involved in 
inflammatory responses and release histamine, which causes dilation of blood vessels, 
and heparin, which prevents blood clotting. Monocytes are involved in phagocytosis, 
antigen presentation and cytokine production (Kumar, Abbas & Aster, 2012). 
 
Figure 2. Blood cell development. A blood stem cell goes through several steps to 
become a red blood cell, platelet, or white blood cell. Figure taken from (National Cancer 
Institute, 2017).  
 
AML is caused by a collaboration of two classes of mutations, class I and class II. 
Class I mutations activate signal transduction pathways and lead to proliferation and 
survival of blast cells. Class II mutations affect transcription factors and impairs 
hematopoietic differentiation (Takahashi, 2011). The cooperation between the two 
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classes of mutations leads to the development of leukemic cells that are able to proliferate 
and survive without differentiating (Grafone, Palmisano, Nicci & Storti, 2012).  
The initiating driver mutation of AML is suspected to be the class II mutations, 
which commonly occur in nucleophosmin 1 (NPM1), DNA methyltransferase-3a 
(DNMT3a), isocitrate dehydrogenase 2 (IDH2) or ten-eleven-translocation-2 (TET2). 
NPM1 is localized in the nucleolus and functions as a molecular chaperone of proteins. 
NPM1 also plays a role in ribosome biogenesis, genomic stability, cell cycle progression 
and DNA repair (Rau & Brown, 2009). Mutations in NPM1 lead to its displacement from 
the nucleolus, which blocks its ability to exert its normal function (Verhaak et. al., 2005). 
IDH2 is located in the mitochondria and converts isocitrate to alpha-ketoglutarate in the 
citric acid cycle. Mutant IDH2 has been found to catalyze the reduction of alpha-
ketoglutarate to 2-hydroxyglutarate, which is involved in altered gene expression and 
blocked differentiation of hematopoietic progenitor cells through DNA and histone 
hypermethylation (Medeiros et. al., 2016). TET2 is a tumor-suppressor gene that 
catalyzes the conversion of 5-methylcytosine to 5-hydroxymethylcytosine and plays a 
role in DNA demethylation. Deletion or mutation of TET2 in patients with AML can lead 
to an alteration of hematopoietic stem cell function and differentiation through epigenetic 
modification (Weissman et. al., 2011). DNMT3A catalyzes the addition of a methyl 
group to the cytosine residue of CpG dinucleotides, which cluster into CpG islands. CpG 
islands are concentrated upstream of genes and a mutation in DNMT3A can lead to 
hypermethylation, which causes reduced expression of the downstream genes, commonly 
of tumor-suppressor genes (Ley et. al., 2010). Mutations in NPM1, DNMT3a, IDH2 or 
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TET2 leads to a survival advantage for the hematopoietic stem cell (Kayser & Levis, 
2014).  
The initiating driver mutation is followed by a cooperating class I mutation and 
leads to the full transformation into AML. The most common cooperating class I 
mutation is an ITD of the FLT3 gene. The FLT3-TID mutation constitutively activates 
the FLT3 receptor and its downstream signaling pathways leading to dysregulation of 
cellular proliferation (Kayser & Levis, 2014).  
 
FLT3 Mutation 
The FLT3 gene is located on chromosome 13q12 (Wander, Levis & Fathi, 2014). 
FLT3 plays a critical role in normal hematopoiesis and cellular growth and its activation 
regulates a number of cellular processes such as phospholipid metabolism, transcription, 
proliferation and apoptosis (Meshinchi & Appelbaum, 2009). The FLT3 receptor belongs 
to the class III receptor tyrosine kinase (RTK) family, and is localized in hematopoietic 
and neural tissues (Kindler, Lipka & Fischer, 2010). It is a cell-surface receptor that is 
comprised of five extracellular immunoglobulin-like domains, a transmembrane domain, 
an intracellular juxtamembrane domain and two intracellular tyrosine kinase domains 
(Fathi & Chen, 2011).  
The juxtamembrane domain maintains the inactive conformation of the FLT3 
receptor due to steric inhibition. The domain is subdivided into three parts, the 
juxtamembrane-binding motif, the switch motif and the linker/zipper peptide segment. 
The juxtamembrane-binding motif is involved in activation and inactivation and 
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stabilizes the inactive kinase conformation. The switch motif consists of two 
phosphorylation sites. The linker/zipper peptide segment can pivot about its attachment 
point allowing it to undergo large amplitude rotations (Kayser et. al., 2009). The 
intracellular tyrosine kinase domains are made up of an ATP-binding loop and a catalytic 
domain separated by a kinase insert domain (Zhang et. al., 2000). In the inactivated state, 
the FLT3 receptor is monomeric and unphosphorylated and the tyrosine kinase domain is 
inactive (Meshinchi & Appelbaum, 2009). The wild-type FLT3 receptor remains in the 
inactive monomeric form (Grafone, Palmisano, Nicci & Storti, 2012). 
The FLT3 ligand is a type I transmembrane protein that is expressed in cells of 
the hematopoietic bone marrow microenvironment (Meshinchi & Appelbaum, 2009). The 
family of type I transmembrane proteins are growth factors that stimulate proliferation 
and differentiation upon binding (Grafone, Palmisano, Nicci & Storti, 2012). Following 
the binding of the FLT3 ligand, the FLT3 receptor dimerizes, which leads to a 
conformational change in its activation loop. The conformational change exposes the 
FLT3 active site and allows ATP to access it (Pratz & Levis, 2008). After dimerization, 
the receptor undergoes autophosphorylation in the inner leaflet of the membrane leading 
to activation of the tyrosine kinase domain and subsequent downstream signaling (Fathi 
& Chen, 2011). This process is shown in Figure 3.  
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Figure 3. Activation of FLT3. A) Inactive conformation; B) Active conformation. 
Juxtamembrane domain (yellow), activation-loop (green), catalytic loop (red). P, 
phosphorylation site; N, N-lobe, TK1 domain; C, C-lobe, TK2 domain; ITD, internal 
tandem duplications; JM-PMs, point mutation in the juxtamembrane domain; TKD, point 
mutation in the tyrosine kinase domain; FL, FLT3 ligand. Figure taken from (Grafone, 
Palmisano, Nicci & Storti, 2012) 
 
The activated FLT3 receptor recruits a number of proteins, such as Src homology 
2 containing protein (SHC) and growth factor receptor bound protein 2 (GRB2). As each 
protein binds to the receptor, it becomes activated, resulting in a cascade of 
phosphorylation reactions that activate downstream signaling mediators (Meshinchi & 
Appelbaum, 2009). Downstream signaling mediators of the FLT3 pathway include 
phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene homolog 
(AKT), Ras/mitogen-activated protein kinase (MAPK)/extracellular-signal regulated 
kinase 1 and 2 (ERK1/2) and signal transducer and activator of transcription 5 (STAT5), 
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which are involved in cell cycle progression, inhibition of apoptosis and differentiation of 
myeloblasts, shown in Figure 4 (Fathi & Chen, 2011). Activation of the tyrosine kinase 
domain is negatively modulated by tyrosine phosphatase, which acts by removing the 
phosphates and allowing the juxtamembrane domain to transform into the autoinhibitory 
site (Grafone, Palmisano, Nicci & Storti, 2012).  
 
Figure 4. FLT3 downstream signaling pathways. Schematic representation of the 
FLT3 receptor and downstream signaling pathways. Figure taken from (Rattu et. al., 
2014). 
 
The PI3K/AKT signaling pathway regulates cell growth, proliferation, survival 
and apoptosis. Following activation by FLT3, PI3K converts phosphatidylinositol 4,5-
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bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 then recruits 
AKT to the cell surface and activates it. Mammalian target of rapamycin (mTOR) acts 
both upstream and downstream of AKT and regulates the protein synthesis necessary for 
cell growth, proliferation and survival (Genentech, 2017).  
The MAPK signaling pathway plays a role in the regulation of gene expression, 
cellular growth and survival. The pathway starts with the activation of the protein Ras by 
FLT3, which then recruits and activates Raf proteins. Next, Raf phosphorylates mitogen-
activated protein kinase kinase (MEK), which in turn phosphorylates extracellular-signal 
regulated kinase (ERK). Following phosphorylation, ERK leads to expression of genes 
encoding proteins that regulate cell proliferation and survival (Genentech, 2017).  
The janus associate kinase (JAK)-STAT pathway is involved in cellular division 
and apoptosis. The pathway begins with the activation of JAK, which is a cytoplasmic 
tyrosine kinase that associates with cytokine receptors (Birkenkamp et. al., 2001). The 
activated JAK then recruits and phosphorylates the STAT5 protein. After 
phosphorylation, the STAT5 protein dimerizes and is translocated to the nucleus where it 
interacts with regulatory elements for gene expression (Furqan, Mukhi, Lee & Liu, 2013).  
Gain-of-function mutations in FLT3 lead to constitutive activation of the receptor. 
The two most common mutations that contribute to the pathogenesis of AML are a point 
mutation within the activation loop of the tyrosine kinase domain (TKD) and an ITD 
within the juxtamembrane domain shown in Figure 5. The constitutive activation triggers 
the downstream signaling pathways leading to increased proliferation and suppression of 
apoptosis (Fathi & Chen, 2011). 
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Figure 5. FLT3 mutations. A schematic diagram of the FLT3 receptor tyrosine kinase 
showing the location of the internal tandem duplication of genes within the 
juxtamembrane domain and point mutations and gene insertions in the second kinase 
domain. Figure taken from (Litzow, 2005).  
 
Point mutations within the activation loop of the kinase domain in FLT3 occur in 
7% of AML patients. The mutation results in a single amino acid substitution, most 
commonly a substitution of aspartic acid by tyrosine at codon 835, but other point 
mutations, deletions and insertions within codon D835 and its surrounding codons have 
been described (Levis, 2013). The activation loop functions as a flexible gate, and when 
it is open it allows access to ATP and substrate to the nucleotide-binding site. In the 
closed conformation, the activation loop prevents ATP binding (Nguyen et. al., 2017). A 
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point mutation in the activation loop causes it to maintain the open conformation and 
leads to constitutive kinase activation in the absence of FLT3 ligand binding (Nguyen et. 
al., 2017). FLT3-TKD point mutations are associated with high peripheral blood and 
bone marrow blast counts (Kindler, Lipka & Fischer, 2010).  
An ITD in the juxtamembrane domain is associated with a poor prognosis and is 
found in 30% of adult AML patients and in 15% of pediatric patients (Fathi & Chen, 
2011). Patients with the FLT3-ITD mutation have a two-year disease-free survival rate of 
20% and a four-year overall survival rate of 20% (Marcucci et. al., 2007). Relapse in 
patients with the FLT3-ITD mutation is always fatal and the cancer emerges even more 
aggressive (Levis, 2015). Patients that present with the FLT3-ITD mutation have 
pronounced leukocytosis, a high percentage of peripheral and bone marrow blasts and 
normal cytogenetics (Levis & Small, 2003). ITD repeats vary in length, ranging from 
three to more than 400 base pairs, but all repeats are always present in multiples of three 
in order to maintain the reading frame (Yamamoto et. al., 2001). The allele ratio is the 
number of ITD-mutated alleles compared with the number of wild-type alleles. Patients 
with a higher allele burden have a worse prognosis (Santos et. al., 2011).  
The FLT3-ITD mutation leads to ligand-independent dimerization and 
constitutive activation of the FLT3 receptor and thus the activation of the downstream 
signaling pathways. In contrast to wild type FLT3, FLT3-ITD potently activates the 
STAT5 pathway, due to the unmasking of two STAT5 phosphorylation sites located in 
the juxtamembrane domain by the mutation, which in turn induces its target genes such 
as cyclin D1, c-myc and the anti-apoptotic gene p21, which are important for cell growth 
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(Takahashi, 2011). The potent activation of the STAT5 pathway leads to the aberrant cell 
growth of the leukemic cells. Through constitutive activation of the PI3K/AKT pathway, 
the FLT3-ITD transformation leads to a significant increase in aerobic glycolysis, 
promoting the Warburg effect and the decrease in cellular respiration (Ju et. al., 2017). 
AKT upregulates mitochondrial hexokinase and renders the leukemia cells highly 
dependent on glycolysis (Ju et. al., 2017).  
 
Current treatments 
 Due to the heterogeneity of AML, there are varying treatment options and 
personalized therapeutic regimens available (Yang & Wang, 2018). The current standard 
treatment for AML is intensive chemotherapy with or without HSCT. 
Chemotherapy 
 Chemotherapy is a treatment that utilizes potent drugs or chemicals to kill or 
damage cancer cells (Leukemia & Lymphoma Society, 2017). The most common 
chemotherapy drugs used for AML patients include cytarabine and an anthracycline, 
which includes daunorubicin, doxorubicin or idarubicin. Additional chemotherapy drugs 
that may be used include etoposide, hydroxyurea, methotrexate and many others (ACS, 
2016). Chemotherapy has remained the standard of care since it was introduced in 1973 
(Stansfield & Pollyea, 2017). Cytarabine acts through direct DNA damage and primarily 
kills cells that are in the process of undergoing DNA synthesis in the cell cycle, S phase, 
and can also block cells from entering S phase from the G1 phase (Drugbank, 2018). 
Anthracyclines are a class of drugs that damage the DNA in cancer cells through 
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inhibition of replication and damaging the cells in a way that promote cell death (Lah, 
2011).  
Chemotherapy treatment for AML patients is divided into two phases, induction 
and consolidation. The goal of the induction phase is to clear the blood of leukemia cells 
and reduce the number of blasts in the bone marrow to normal. Following chemotherapy, 
a bone marrow biopsy is done to determine whether only a small portion of blasts remain. 
If there are still leukemic cells present in the biopsy then additional rounds of 
chemotherapy may be given (American Cancer Society, 2017). For adult patients, 
induction is administered as a 7+3 regimen, which means that cytarabine is given as a 
continuous infusion for seven days and the anthracycline is given on days one through 
three (Stansfield & Pollyea, 2017). There is still no known chemotherapy regimen that 
would best benefit patients older than 60 (Yang & Wang, 2018). The consolidation phase 
is started after the patient has recovered from the induction phase. It is meant to kill the 
small number of leukemia cells that are still around but can’t be detected (American 
Cancer Society, 2016). Generally, two or more chemotherapy drugs are used to treat 
AML patients. 
Chemotherapy has a wide range of side effects because the drugs attack cells in 
the body that divide quickly including cancer cells, bone marrow, hair follicles and the 
lining of the mouth and intestines. Side effects of chemotherapy include increased risk of 
infections, easy bruising, bleeding, fatigue, hair loss, mouth sores, loss of appetite, nausea 
and vomiting (American Cancer Society, 2016). Hyperleukocytosis is present in 5-20% 
of patients with newly diagnosed AML. The high number of leukemia cells can cause 
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issues with blood circulation, which would make chemotherapy less effective. 
Leukaparesis may be used prior to chemotherapy in order to decrease the number of 
leukemia cells. This process passes the patient’s blood through a machine and removes 
white blood cells, including leukemia cells, and then returns the rest of the blood to the 
patient (Jin et. al., 2018).  
Stem Cell Transplant 
There are two types of HSCTs, allogeneic and autologous. An allogeneic stem 
cell transplantation comes from a donor other than the patient, someone whose tissue type 
closely matches the patient’s. An autologous stem cell transplant is when the patient’s 
stem cells are removed from their bone marrow prior to their cancer treatment and then 
are reinfused following treatment. This is not the preferred treatment in AML because it 
is possible that leukemic cells would be included with the stem cells (Hatzimichael & 
Tuthill, 2010). This treatment is normally used for patients that are in remission and do 
not have an allogeneic match. 
 Since chemotherapy has such serious side effects associated with it at higher 
doses, it limits the size of the dose that a patient is able to handle. Higher doses of 
chemotherapy are able to kill more leukemic cells but it also severely damages the bone 
marrow leading to low blood cell counts, which can cause life threatening infections and 
bleeding (American Cancer Society, 2016). The addition of HSCT allows the use of 
higher doses of chemotherapy that would otherwise be fatal. Once the chemotherapy is 
complete, the patient gets an infusion of blood-forming stem cells to restore their bone 
marrow following the induction of myelosuppression (Hatzimichael & Tuthill, 2010).  
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 Possible side effects of HSCT are similar to those from chemotherapy but have 
the tendency to be more severe including loss of appetite, hair loss, low blood cell counts 
and associated fatigue, increased risk of bleeding and infection (American Cancer 
Society, 2016). Potential long term-effects include chronic graft-versus-host disease in 
allogeneic transplants, loss of fertility, damage to the lungs leading to shortness of breath 
and damage to the thyroid gland leading to problems with metabolism (American Cancer 
Society, 2016). 
Radiation 
Radiation is normally not included in the treatment of AML patients, but it has 
been utilized in some cases, such as before a stem cell transplantation, if the cancer 
spread to the brain or to reduce pain in the area of bone that was invaded by the cancer. 
Radiation therapy uses high-energy particles or waves to kill cancer cells (American 
Cancer Society, 2016). Possible side effect of radiation therapy depends on where the 
radiation is aimed and can include sunburn-like skin changes, sores, trouble swallowing, 
lowered blood counts and an increased risk of infection (American Cancer Society, 
2016).  
 
FLT3 Inhibitors 
 The discovery that FLT3 mutations exist in a large percentage of AML patients 
led to the emergence of novel FLT3 inhibitors (Meshinchi & Appelbaum, 2009). FLT3 
inhibitors are tyrosine kinase inhibitors, which can be categorized into either type I or 
type II. Type I inhibitors compete directly with ATP to bind and make contact with the 
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tyrosine kinase hinge region. Type II inhibitors compete indirectly with ATP by binding a 
hydrophobic allosteric site, which results in the inability to autophosphorylate and thus 
interrupts signal transduction (Nguyen et. al., 2017). Type I inhibitors are able to bind to 
the target when the activation loop is either open or closed but type II inhibitors can only 
bind to the target when the activation loop is in the closed conformation (Nguyen et. al., 
2017). FLT3 inhibitors are classified into either first or second-generation inhibitors. The 
first-generation inhibitors lack specificity for FLT3 and include sunitinib, sorafenib, 
lestaurtinib and midostaurin. Second-generation inhibitors potently target FLT3 and thus 
do not have efficacy against targets downstream of FLT3 or in parallel signaling 
pathways in leukemic cells. These include quizartinib, crenolanib and gilteritinib 
(Larossa-Garcia & Baer, 2017).  
Sunitinib 
 Sunitinib (SU11248) is a multitargeted oral angio-inhibitory tyrosine kinase 
inhibitor (Kayser & Levis, 2014). Sunitinib was approved for patients with advanced 
renal cell carcinoma and for patients with gastrointestinal stromal tumors (Le Tourneau, 
Raymond & Faivre, 2007). In AML patients with gain of function mutations such as 
FLT3-ITD, sunitinib causes growth arrest and apoptosis of the leukemic cells (Nishioka, 
Ikezoe, Yang & Yokoyama, 2009). 
Sorafenib 
 Sorafenib is a first-generation multikinase inhibitor that was approved by the 
FDA for hepatocellular carcinoma and renal cell carcinoma (Antar et. al., 2016). In 
patients with AML, sorafenib functions as a type II FLT3 inhibitor and also inhibits RAF, 
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VEGFR and other class III receptor tyrosine kinase receptors (Larrosa-Garcia & Baer, 
2017). Sorafenib suppresses the autophosphorylation of FLT3, thus suppressing the 
downstream signaling, which leads to leukemic cell death (Auclair et. al., 2007).   
Lestaurtinib  
 Lestaurtinib is a polyaromatic indolocarbazole compound that acts by inhibiting 
autophosphorylation of normal and mutant FLT3 receptors and has high selectivity 
against FLT3 when compared to other receptor tyrosine kinase receptors (Meshinchi & 
Appelbaum, 2009). 
Midostaurin 
 Midostaurin is a staurosporine derivative and a broad-spectrum type I tyrosine 
kinase inhibitor (NIH, 2017). Midostaurin was the first therapy developed to target FLT3-
mutated AML and was approved by the FDA in April 2017 to be used in addition to 
chemotherapy (Shaffer & Broderick, 2017).  Midostaurin was initially developed to 
inhibit protein kinase C but it was subsequently found to inhibit the type III tyrosine 
kinase receptors including FLT3, vascular endothelial growth factor (VEGF) and platelet-
derived growth factor receptor (PDGFR) (Fathi & Chen, 2011). The drug inhibits FLT3 
receptor signaling and cell proliferation and induces apoptosis in leukemic cells 
expressing ITD and TKD mutations (Shaffer & Broderick, 2017). Following 
administration, midostaurin is rapidly absorbed and binds primarily to alpha-1 acidic 
glycoprotein (AAG) (Gallogly & Lazarus, 2016). The mechanism of action for 
midostaurin is shown in Figure 6. Midostaurin is metabolized into two metabolites in the 
liver by CYP3A4 (Grunwald & Levis, 2013).  
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Figure 6. Midostaurin (Rydapt) Mechanism of Action. Figure taken from (Novartis, 
2017).  
 
Midostaurin is taken as a pill twice a day and its side effects include a low white 
blood cell count, which can lead to infections, headache, muscle or bone pain, high blood 
sugar levels and upper respiratory infections (American Cancer Society, 2017).  
Quizartinib 
 Quizartinib is a potent selective second-generation FLT3 inhibitor and its 
selectivity is shown in Figure 7 (Kampa-Schittenhelm, 2013). It was the first drug that 
was designed specifically for FLT3 and has a 10-fold lower affinity for other receptor 
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tyrosine kinases (Levis, 2015). Quizartinib has been found to have a long plasma half-life 
with sustained FLT3 inhibition and is also able to maintain its potency in plasma (Fathi & 
Chen, 2011).  
 
Figure 7. Kinase Interaction Maps. Shown here are the maps for 5 small-molecule 
kinase inhibitors ranging from very nonselective (staurosporine) to highly selective 
(quizartinib). The black arrow on each dendrogram denotes the approximate location for 
the FLT3 receptor. Lestaurtinib, midostaurin, sorafenib, and quizartinib have all been 
studied as FLT3 inhibitors. Figure taken from (Levis, 2017).  
 
Crenolanib 
 Crenolanib is a benzamide quinolone derivative and a second-generation type I 
FLT3 inhibitor. Crenolanib has been found to have cytotoxicity toward both FLT3-ITD 
and FLT3-TKD mutated AML as well as a PDGFR inhibitor (Larrosa-Garcia & Baer, 
2017).  
Gilteritinib  
 Gilteritinib is a type I FLT3 and AXL inhibitor. Gilternitib has been shown to 
have efficacy with chemotherapy and as a monotherapy for patients with FLT3-ITD 
mutated AML (Larrosa-Garcia & Baer, 2017).  
 
Resistance 
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 An obstacle in the treatment of AML is drug resistance, which is a potential 
barrier for all types of therapies including the standard treatment of chemotherapy and 
tyrosine kinase inhibitors. Resistance has been prevalent in patients that have FLT3-ITD 
mutations as well as for those who have wild type FLT3. Resistance to therapy leads to 
either a lack of efficacy or a loss of prior efficacy (Grunwald & Levis, 2013). Factors that 
lead to resistance can either be intrinsic or extrinsic. Intrinsic mechanisms are divided 
into primary resistance, patients who are resistant to therapy from the outset, and 
secondary resistance, patients who develop resistance during the course of the treatment 
(Grunwald & Levis, 2013). The mechanisms of resistance will be expanded on further in 
the next section.  
 
Specific aims 
 The first aim of this thesis is to provide a comprehensive literature review of the 
clinical effectiveness of chemotherapy, HSCT and FLT3 inhibitors for patients with 
FLT3-ITD mutated AML. The second aim is to compare and contrast the current standard 
treatment of chemotherapy with or without HSCT with FLT3 inhibitors and explore the 
potential options for future treatments and combinatorial regimens. Finally, this thesis 
will explore the mechanisms of drug resistance and the impact it has on treatment options 
for AML.  
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PUBLISHED STUDIES 
 
There are numerous studies that have been conducted to measure the efficacy of 
the different treatment options for patients with FLT3-ITD mutated AML. 
 
Clinical effectiveness of current treatments 
Chemotherapy 
 Boissel et. al. conducted a retrospective evaluation of patients with FLT3-ITD 
mutated AML who received the standard treatment of chemotherapy. The study found 
that there was no difference in the complete remission rate or relapse-free survival of 
patients that had FLT3-ITD mutated AML compared to those with wild-type FLT3. In 
FLT3-ITD patients treated with only chemotherapy, their overall survival was 
significantly worse compared to wild-type FLT3 patients due to relapse (Boissel et. al., 
2002). With the standard chemotherapy treatment, the average number of patients that 
achieve complete remission falls between 40% and 80%. For elderly patients, the median 
survival following chemotherapy is only 4.6 months and the one-year survival rate is only 
28% (Kantarjian et. al., 2010).  
Stem Cell Transplantation 
 The addition of HSCT to the standard treatment of chemotherapy has been 
effective in lowering the relapse rate and improving the overall survival for patients with 
the FLT3-ITD mutation. A study conducted in the United Kingdom found that patients 
who received an allogeneic stem cell transplantation during their first complete remission 
 27 
had a better clinical outcome compared to the patients who were treated with 
chemotherapy alone (Gale et. al., 2005).  
DeZern et. al. conducted a cohort study where one group contained patients with 
FLT3-ITD mutations and the other group contained patients with wild-type FLT3. All of 
the patients received an allogeneic HSCT following two intensive regimens of induction 
chemotherapy. Following the treatment, overall survival, event-free survival, relapse rate 
and non-relapse mortality were measured. The study found that the median relapse free 
survival for FLT3-ITD patients that did not have a transplant were significantly shorter 
(8.6 months) compared to those who did have the transplant (54.1 months) (DeZern et. 
al., 2011). 
A contributing factor to morbidity and mortality following allogeneic HSCT is 
graft versus host disease (GVHD). This develops when the donor’s immune cells 
mistakenly attack the patient’s normal cells. GVHD is hard to treat so prevention and 
early detection are essential (Najafabadi, Shamsasenjan & Akbarzadehalaleh, 2017). The 
incidence of GVHD rises with increasing age and can be either mild, moderate, severe or 
life-threatening. 
 
Clinical effectiveness of FLT3 inhibitors 
Sunitinib 
 Sunitinib was evaluated in a single-dose phase I study for patients with the FLT3-
ITD mutation and with wild-type FLT3. More than 50% of patients who were given 
200mg of sunitinib exhibited strong inhibition of FLT3 phosphorylation (O’Farrell et. al., 
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2003). In another phase I study, fifteen patients with refractory AML were treated with 
sunitinib as a single-agent. The results showed that sunitinib is ineffective as a single 
agent because it only induced a partial clinical response that lasted for four to sixteen 
weeks (Fiedler et. al., 2005).  
A phase I/II clinical study evaluated sunitinib in combination with chemotherapy. 
The participants were elderly patients with FLT3-mutated AML. The complete remission 
rate for patients with FLT3-ITD was 53% and for FLT3-TKD patients it was 71%. The 
median survival of the fifteen patients in this study was 18.8 months and median relapse-
free survival was 11 months (Fielder, Kayser & Kebenko, 2012).  
Sorafenib 
 A phase I trial was conducted in sixteen patients with refractory or relapsed AML 
and found that sorafenib significantly reduced myeloid blast cells in the bone marrow and 
peripheral blood of patients with the FLT3-ITD mutation (Zhang, et. al., 2008). Another 
study treated patients with FLT3-ITD mutated AML following either chemotherapy or 
allogeneic HSCT with sorafenib monotherapy. The results showed hematologic remission 
in 37% of patients, bone marrow remission in 8% and complete remission in 23% of 
patients. Of the patients who underwent sorafenib monotherapy following chemotherapy 
alone, 47% developed resistance to sorafenib but patients who had the treatment 
following allogeneic HSCT experienced less resistance (38%) (Metzelder et. al., 2012).  
A phase II study assessed sorafenib monotherapy in patients with relapsed or 
refractory FLT3-ITD mutated AML. In twelve of thirteen patients there was a decrease in 
bone marrow blast cells. The response to the drug was lost in the majority of patients 
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after a mean of seventy-two days but the FLT3 receptor and downstream mediators 
remained suppressed (Man et. al. 2012). The study also found that in three patients there 
was a detectable secondary mutation in D835 following treatment (Man et. al. 2012).  
In a phase I/II study, sorafenib was further evaluated in combination with 
intensive chemotherapy. It was found that in young FLT3-mutated AML patients and in 
patients with wild-type FLT3 AML, high rates of complete remission were induced. After 
the first year, the survival rate was 74% (Ravandi et. al., 2010). A randomized double 
blind placebo-controlled phase II trial tested the efficacy of sorafenib with chemotherapy. 
Sorafenib was administered after the induction and consolidation phases of chemotherapy 
and as twelve-month maintenance therapy. The participants included patients with or 
without FLT3 mutations between the ages of eighteen to sixty years. The patients that 
were on sorafenib had a median event-free survival of twenty-one months whereas the 
patients on the placebo had a median event-free survival of nine months. The differences 
between patients with or without FLT3 mutations were not statistically significant (Rollig 
et. al. 2015). 
There have been limited results in regards to the efficacy of sorafenib treatment in 
older patients. A randomized double-blinded study was conducted for older patients with 
AML. Patients were either treated with sorafenib in combination with standard 
chemotherapy or with a placebo and standard chemotherapy. The study did not find that 
sorafenib added any beneficial effects for patients (Serve, Wagner & Sauerland, 2010).  
Lestaurtinib  
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 A phase I/II trial was conducted to evaluate lestaurtinib in patients with the FLT3 
mutations that had refractory, relapsed or poor-risk AML. When the drug was used alone 
on heavily pretreated patients there was a measurable clinical response in five of the 
fourteen participants, which included a reduction in blasts found in the bone marrow and 
peripheral blood but no complete remission (Smith et. al., 2004). The clinical responses 
were short lived and only lasted from two weeks to three months.  
 A follow-up phase II study was conducted in which lestaurtinib was administered 
as a stand-alone first-line treatment for older patients that were not fit for intensive 
chemotherapy. This treatment was given regardless of FLT3 mutation status. Three out of 
five patients that had FLT3 mutated AML and five out of twenty-two patients with wild-
type FLT3 showed clinical activity with peripheral blood and bone marrow reductions of 
myeloid blast cells (Knapper et. al., 2006).  
An in vitro cytotoxicity study was conducted to determine the effect of 
lestaurtinib when combined with chemotherapy. Lestaurtinib acted in a synergistic 
fashion when it was used simultaneously or immediately following chemotherapy. When 
lestaurtinib was used as a pretreatment followed by chemotherapy the action was 
antagonistic (Levis, Pham, Smith & Small, 2004). When lestaurtinib was given first, it 
induced cell cycle arrest, which blunted the S-phase selective effects of the chemotherapy 
agents. This study was followed with a randomized trial of patients with FLT3 mutated 
AML after their first relapse that tested the efficacy of lestaurtinib used in addition to 
chemotherapy. Patients either received chemotherapy alone or in addition to lestaurtinib. 
Twenty-nine of the patients with the combined therapy showed less than 5% myeloid 
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blast cells compared to twenty-three patients who had chemotherapy alone. The 
combination therapy did prolong survival (Levis et. al., 2011).  
Midostaurin 
 A phase IB dose escalation trial of midostaurin in combination with induction and 
post-remission chemotherapy was conducted in patients with newly diagnosed AML 
(Stone et. al., 2012). The study found that the midostaurin dose of 50mg twice a day was 
safe and effective with an 80% complete remission rate (Stone et. al., 2012). The patients 
were given the midostaurin either with chemotherapy or after it but the dosage schedule 
did not alter the complete remission rate.  
 A phase II trial investigated midostaurin as a single agent. This study was 
conducted with twenty high risk AML patients with the FLT3-ITD mutation. Fourteen of 
the patients (70%) had a 50% decrease in their peripheral blast counts, six (30%) showed 
a 50% reduction in bone marrow blast counts and two patients (10%) showed complete 
clearance of blasts in their bone marrow (Stone et. al., 2005). When midostaurin was used 
in addition to chemotherapy there was a high complete remission rate.  
A randomized phase II trial was conducted for patients with relapsed or refractory 
AML. The participants had either wild type FLT3 or FLT3-ITD mutated AML. The 
patients were randomized to receive different dosages of midostaurin as a monotherapy. 
The blast response in patients with the FLT3-ITD mutation were higher at 71% compared 
to patients with wild-type FLT3 at 42%. In these patients the blood or bone marrow blasts 
were reduced by more than 50% (Fischer et. al., 2010). 
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A randomized, double-blind phase III trial compared the overall survival of 
patients aged 18 to 60 with newly diagnosed AML that had either an FLT3-ITD or FLT3-
TKD mutation. The patients were randomized into receiving midostaurin or a placebo in 
three different treatment regimens. Midostaurin was either given after cytarabine and 
daunorubicin induction, following high-dose cytarabine consolidation therapy or as one-
year maintenance therapy (Wander, Levis & Fathi, 2014). There was no difference 
between the placebo or midostaurin groups in regards to complete remission but there 
was a significant difference in overall survival for patients on midostaurin, 74.7 months, 
versus those that were on the placebo, 26 months (Stone et. al., 2015). The survival rate 
was consistent for all three stratification groups. 
A phase III trial was conducted in patients with newly diagnosed FLT3-mutated 
AML to test the efficacy of adding midostaurin to standard chemotherapy. Patients had 
either the FLT3-ITD mutation or the FLT3-TKD mutation. The overall survival of 
patients in the midostaurin group, 74.7 months, was significantly longer than the placebo 
group, 25.6 months (Stone et. al., 2017). The event-free survival in the midostaurin 
group, 8.2 months, was also longer than in the placebo group, 3 months. The addition of 
midostaurin to chemotherapy for patients with FLT3-mutations results in a 22% lower 
risk of death compared to patients who received a placebo (Stone et. al., 2017). 
Midostaurin is metabolized in the liver by CYP3A4 into two metabolites 
(Grunwald & Levis, 2013). CYP3A4 can be induced by either midostaurin or its 
metabolites and this can lead to changing levels of the drug in a patient’s system. Due to 
this, patients that are on medication that induce or inhibit CYP3A4 were excluded from 
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midostaurin trials (Fischer et. al., 2010). Heidel et. al. discovered that when midostaurin 
is used as a single-agent, an Asn-676 mutation in the ATP-binding pocket of FLT3 
tyrosine kinase domain confers resistance to the drug. This and other studies have led to 
the conclusion that midostaurin should be used for sequential and/or combinatorial 
treatment of FLT3-ITD AML and not as a monotherapy (Kindler, Lipka & Fischer, 
2010).  
  Quizartinib 
 Quizartinib has been found to have a significantly longer half-life in vivo when 
compared with other tyrosine kinase inhibitors as well as a greater capacity for sustained 
FLT3 inhibition (Cortes et. al., 2013). In a phase I trial of patients with relapsed and 
refractory AML patients, quizartinib was given to patients with either FLT3-mutated 
AML or wild-type FLT3 at escalating dosages. The study found that there was an effect 
on cardiac repolarization that limited the level of dosage to 200mg daily. The most 
common adverse event that occurred was a prolonged QT interval, which was found in 
12% of patients (Cortes et. al., 2013). In patients with the FLT3-ITD mutation the rate of 
complete remission was 53%, whereas in patients with wild-type FLT3 the complete 
remission rate was 14% (Cortes et. al., 2013). This study highlighted the possibility of 
quizartinib being used to treat FLT3-ITD mutated AML as a single-agent.  
Sandmaier et. al. conducted a phase I study for patients in remission to determine 
the efficacy of quizartinib when used as a component of maintenance therapy following 
an allogeneic HSCT. The study had a small sample size of thirteen patients but 
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demonstrated that utilizing quizartinib as maintenance therapy was efficacious in 
reducing the relapse rate (Sandmaier et. al., 2014). 
Quizartinib was further evaluated in a phase II trial for patients with the FLT3-
ITD mutation and either relapsed or refractory AML. In this study the blast counts were 
decreased sufficiently enough in 35% of the patients to allow for a HSCT and a 
prolonged overall survival (Levis et. al., 2014). Hills et. al. investigated the effectiveness 
of quizartinib for patients who relapsed after HSCT or salvage chemotherapy. In these 
patients with a normally dismal prognosis, the addition of quizartinib led to a remission 
rate of 44% and a median overall survival of twenty-three weeks for patients with FT3-
ITD AML (Hills et. al., 2015). 
A recent phase I open-label dose escalation study was conducted to determine the 
efficacy of quizartinib in combination with the standard induction and consolidation 
chemotherapy treatment in newly diagnosed AML patients. Sixteen patients (84%) 
experienced a significant clinical response to the therapy, fourteen patients (74%) 
achieved complete remission and two patients (11%) were determined to be leukemia-
free. Out of the nine patients with the FLT3-ITD mutation, six of them (67%) achieved 
complete remission and two (22%) were determined to be leukemia-free following 
treatment (Altman, 2017). 
Crenolanib 
 Crenolanib has demonstrated inhibition of FLT3 in both FLT3-ITD mutated and 
wild-type FLT3 cells at similar plasma concentrations to quizartinib. The difference 
between the two drugs is that crenolanib has not demonstrated any QT prolongation in 
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patients (Galanis et. al., 2012). Crenolanib has also demonstrated efficacy against 
primary blasts that have developed resistance to quizartinib due to a secondary activating 
mutation in D835 (Zimmerman et. al., 2013).    
 A phase II open label study was conducted in patients with relapsed or refractory 
AML with either FLT3-ITD or FLT3-TKD mutations. The median duration of the study 
therapy was nine weeks and only two patients remained on the study. The reasons for 
study cessation include disease progression in 66% of patients, no response in 16% of 
patients, toxicity in 6% of patients and clinical deterioration due to other co-morbidities 
in 6% of patients. Crenolanib showed clinical efficacy in the pre-treated patients but it 
was not long-lasting (Randhawa et. al., 2014).  
Gilteritinib  
 Preclinical studies of gilteritinib use immunoblotting to show that its in vitro 
efficacy is equal to or greater than midostaurin, sorafenib, quizartinib and crenolanib (Lee 
et. al., 2017). A phase I/II open-label study was conducted with patients who had relapsed 
or refractory AML. The study found that 40% of patients achieved a clinical response, 
10% achieved partial remission and 8% achieved complete remission. The study found 
that there was consistent FLT3 inhibition in all patients (Perl et. al., 2017). 
 
Resistance 
 An important obstacle to consider when comparing the efficacy of treatments for 
FLT3-ITD mutated AML is resistance. Factors that lead to resistance to FLT3 inhibitors 
include extrinsic pharmacokinetic factors, intrinsic receptor pharmacodynamics factors 
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and cell-intrinsic factors (Grunwald & Levis, 2013). Intrinsic mechanisms of resistance 
are classified into primary or secondary. Primary resistance occurs when patients are 
resistant to the therapy from the outset and secondary resistance occurs when patients 
develop resistance during the course of treatment (Table 1) (Larrosa-Garcia & Baer, 
2017). 
 
Table 1. Mechanisms of resistance of FLT3-mutated AML cells. Table adapted from 
(Larrosa-Garcia & Baer, 2017). 
INTRINSIC EXTRINSIC 
PRIMARY 
• Compensatory 
signaling pathway 
activation 
• Upregulation of 
Mcl-1 
• Paracrine signaling 
• Autocrine signaling 
• Adhesion-mediated 
resistance 
• TKD mutations 
• Overexpression of 
FLT3 receptor 
SECONDARY 
• New mutations in 
FLT3-ITD 
• Upregulation of Pim 
kinases 
• Genomic instability 
• Insufficient 
cytotoxicity 
 
• Drug interactions 
• Protein binding 
• Induction of FLT3 
ligand by 
chemotherapy 
• Induction of FGF2 
• Activation of ERK 
by bone marrow 
stroma 
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Extrinsic methods of resistance include pharmacokinetic factors, induction of the 
FLT3 ligand by chemotherapy, the bone marrow microenvironment, induction of 
fibroblast growth factor 2 (FGF2) and activation of ERK. Pharmacokinetic factors 
include drug interactions and protein binding. Drug interactions with other medications 
can either potentiate the efficacy of FLT3 tyrosine kinase inhibitors, increase the side 
effects or make it difficult to find an accurate and effective dose of the medication 
(Grunwald & Levis, 2013). Protein binding can also lead to resistance. Some of the FLT3 
inhibitors are hydrophobic and relatively insoluble and are largely bound to AAG, which 
has the tendency to diminish the free levels of the drug (Grunwald & Levis, 2013).  
Another extrinsic method of resistance is caused by the FLT3 ligand. The FLT3 
ligand is upregulated in response to FLT3 inhibition (Levis, 2011). Studies have 
demonstrated that following the administration of chemotherapy, FLT3 levels rise within 
the bone marrow microenvironment, and with each successive course of chemotherapy, 
the concentrations of the ligand continue to rise. The increase in the FLT3 ligand is likely 
a function of the bone marrow stroma and has been shown to be inversely proportional to 
bone marrow cellularity. Bone marrow aplasia following chemotherapy may induce the 
upregulation of FLT3 ligand expression (Wander, Levis & Fathi, 2014). High 
concentration of FLT3 ligand have been shown to interfere with FLT3 inhibition and 
decrease the efficacy of FLT3 tyrosine kinase inhibitors (Grunwald & Levis, 2013). This 
presents a challenge for combinatorial regimens with chemotherapy and FLT3 tyrosine 
kinase inhibitors and is especially problematic for patients with relapsed AML who were 
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heavily treated with chemotherapy. Potential solutions to overcome this type of resistance 
include using more potent FLT3 tyrosine kinase inhibitors, using less cytotoxic 
treatments or by adjusting the order that chemotherapy and tyrosine kinase inhibitors are 
given (Grunwald & Levis, 2013).  
The bone marrow microenvironment mediates extrinsic resistance mechanisms. In 
addition to increased secretion of the FLT3 ligand following chemotherapy, there is also 
an increased secretion of FGF2, which is able to stimulate AML cells that have the FLT3-
ITD mutation by binding to the fibroblast growth factor receptor (Larrosa-Garcia & Baer, 
2017). The FLT3 ligand and the bone marrow stromal cells are also able to activate the 
downstream signaling mediator, ERK, and overcome the effects of FLT3 inhibitors 
(Larrosa-Garcia & Baer, 2017).  The stromal microenvironment consists of pro-growth 
and anti-apoptotic signals that can lead to upregulation of parallel and downstream 
signaling pathways, independent of FLT3. Signaling within the stromal 
microenvironment occurs via cell-cell contact or cytokine-mediated paracrine effects and 
can lead to the upregulation of compensatory proliferation pathways, which contributes to 
drug resistance as well as disease progression (Wander, Levis & Fathi, 2014). The 
pathways that have been found to be upregulated by this process are MAPK and 
PI3K/AKT (Wander, Levis & Fathi, 2014). 
Intrinsic mechanisms of resistance can be classified into either primary or 
secondary. Primary mechanisms include compensatory signaling pathway activation, 
upregulation of Mcl-1, paracrine signaling, autocrine signaling, adhesion-mediated 
resistance, TKD mutations and overexpression of the FLT3 receptor. Figure 8 
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summarizes the molecular mechanisms of FLT3-ITD mutated cells that lead to intrinsic 
resistance. Phase I and II trial data have shown that when FLT3 tyrosine kinase inhibitors 
are used as a single-agent, primary resistance occurs in 30% of patients with FLT3-
mutated AML (Stone et. al., 2005). In vitro evidence has also shown that FLT3-ITD 
contributes to drug resistance in chemotherapy regimens.  
 
 
Figure 8. Molecular mechanisms of intrinsic resistance to FLT3 tyrosine kinase 
inhibitors. (B) In AML blasts expressing a mutated FLT3-receptor, survival and 
proliferation signals are continuously mediated by the mutant receptor. FLT3-TKIs 
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abrogate constitutive activation of the FLT3-receptor and its downstream signals 
followed by apoptotic cell death. Alternatively, activation of compensatory survival 
pathways (eg, activating NRAS mutations) renders leukemic cells independent of FLT3. 
(C) Mutations in the adenosine triphosphate-binding pocket of the tyrosine-kinase 
domain impair binding of the TKI to the receptor. (D) Autocrine and/or paracrine FLT3-
receptor stimulation via FLT3-Ligand (FL). (E) Over expression of the mutated FLT3-
receptor. Figure taken from (Kindler, Lipka & Fischer, 2010).  
 
Primary resistance can occur through cell-intrinsic mechanisms by persistent 
activation of signaling pathways downstream of the FLT3 receptor. This activation of 
compensatory pathways renders the FLT3-mutated cells independent of FLT3 signaling 
(Kindler, Lipka & Fischer, 2010). Mutational screening revealed that novel mutations 
were acquired within neuroblastoma RAS viral oncogene homolog (NRAS) that led to 
constitutive activation of AKT and ERK. Dysregulation or over-expression of anti-
apoptotic proteins is another common feature found in patients with drug resistant AML. 
The anti-apoptotic proteins that tend to be up-regulated are myeloid cell leukemia 1 (Mcl-
1) and survivin.  
In the bone marrow of patients with AML, two-way communication has been 
found to be established between leukemic cells and endothelial cells. Paracrine signaling 
between leukemic cells and endothelial cells results in the support of survival and 
proliferation of each type of cell, which leads to resistance to chemotherapy (Najafabadi, 
Shamsasenjan & Akbarzadehalaleh, 2017). Leukemic cells can also protect themselves 
from apoptosis through autocrine signaling. Leukemic cells secrete angiogenic factors 
including vascular endothelial growth factor (VEGF). VEGFR has been found to be 
expressed on leukemic cells and the VEGF that is secreted by leukemic cells is able to 
activate its receptor on both leukemic and endothelial cells. Once VEGF binds to its 
 41 
receptor, it can serve as an autocrine growth factor. This provides protection against 
apoptosis and thus confers resistance. VEGF can also bind to its receptor present on 
endothelial cells and induce angiogenesis and stimulate the cells to secrete soluble growth 
factors that are important in proliferation and survival of leukemic cells as shown in 
Figure 9  (Najafabadi, Shamsasenjan & Akbarzadehalaleh, 2017).  
 
Figure 9. Two-way communication between AML cells and endothelial cells. Figure 
taken from (Najafabadi, Shamsasenjan & Akbarzadehalaleh, 2017). 
 
Leukemic cells can also become resistant to chemotherapy through adhesion-
mediated drug resistance. When the receptors on the surface of leukemic cells, such as C-
X-C chemokine receptor type 4 (CXCR4) and very late activation antigen 4 (VLA4), 
bind to their ligand on stromal cells, such as endothelial cells, it leads to activation and 
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survival of the proliferation pathways in the leukemic cells. This allows the leukemic 
cells to avoid apoptosis and resist chemotherapy (Najafabadi, Shamsasenjan & 
Akbarzadehalaleh, 2017). Endothelial cells within the bone marrow are able to provide 
protection for leukemic cells.  
In patients with FLT3-TKD mutated AML, the TKD mutation can prevent binding of 
type II FLT3 inhibitors, conferring resistance. In patients with FLT3-ITD mutations, 
exposure to tyrosine kinase inhibitors can lead to overexpression of the FLT3 receptor. If 
FLT3 is overexpressed then incomplete target inhibition occurs, preventing the tyrosine 
kinase inhibitor from acting effectively (Kindler, Lipka & Fischer, 2010).  
Mechanisms of secondary intrinsic resistance include new mutations, upregulation of 
Pim kinases, genomic instability and insufficient cytotoxicity. In some patients treated 
with FLT3 tyrosine kinase inhibitors, secondary FLT3-TKD mutations have occurred, 
which leads to a reduced or complete loss of response to the therapies (Kayser & Levis, 
2014). Type I inhibitors, such as midostaurin and crenolanib are effective against cells 
that either have the FLT3-ITD or FLT3-TKD mutations so they do not induce resistance 
via a secondary mutation in TKD. In comparison, type II inhibitors such as a quizartinib 
and sorafenib are inactive against FLT3-TKD mutations and thus would have the 
potential to induce secondary TKD mutations leading to an acquired resistance (Larrosa-
Garcia & Baer, 2017).  
Another intrinsic secondary mechanism of resistance is the upregulation of the 
oncogenic serine/threonine kinase Pim-1. Pim-1 is downstream of FLT3-ITD and when it 
is transcriptionally upregulated, it potentiates FLT3 signaling in a positive feedback loop 
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(Natarajan et. al., 2013). In patients with relapsed AML, new structural cytogenetic 
abnormalities are frequently present, which is consistent with genomic instability.  
Insufficient cytotoxicity caused by FLT3 inhibitors can also lead to secondary 
resistance. Studies have shown that when patients are treated with FLT3 tyrosine kinase 
inhibitor monotherapy, they only experience a partial clinical response that has the 
tendency to only last a few weeks. This is due to insufficient plasma drug levels, short 
plasma half-lives or hepatic metabolization. The insufficient cytotoxicity results in an 
incomplete removal of the malignant leukemic cells, which can lead to the development 
of secondary drug resistance (Kindler, Lipka & Fischer, 2010).  
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DISCUSSION 
 
The consensus in the literature is that the most effective way to treat FLT3-ITD 
mutated AML is through a combinatorial approach. In regards to chemotherapy, the 
average number of patients that achieved complete remission fell between 40% and 80% 
and the overall survival was significantly worse for patients with FLT3-ITD mutated 
AML as well as for elderly patients. Chemotherapy has been the standard treatment since 
it was developed over forty years ago and the statistics are unfavorable. It is clear that 
chemotherapy alone is not an effective treatment for patients with any type of AML. The 
addition of HSCT to chemotherapy has been shown to be effective in improving the 
overall survival and decreasing the relapse rate for patients with the FLT3-ITD mutation. 
The combination of chemotherapy and HSCT still has not sufficiently improved the 
overall outcomes for patients with FLT3-ITD AML. 
Since the discovery of the FLT3 mutation, there have been significant advances 
made towards a targeted therapy in the form of a tyrosine kinase inhibitor. The consensus 
in the literature is that although tyrosine kinase inhibitors can elicit a measurable clinical 
response in patients with FLT3-ITD mutated AML, they are not sufficient to treat the 
disease alone. A suggestion put forth by the literature is the utilization of combinatorial 
therapy in order to induce a more durable response to the FLT3 inhibitors.  
The first-generation tyrosine kinase inhibitors showed effectiveness in reducing 
blasts in peripheral blood but were not as successful in reducing blasts present in the bone 
marrow. In early studies, sunitinib and lestaurtinib demonstrated positive clinical 
responses but they were limited by poor target selectivity. Sorafenib showed efficacy in 
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reaching remission in a percentage of patients when taken following either chemotherapy 
or allogeneic HSCT. Resistance was a problem in patients that were given sorafenib as a 
single-agent. The clinical responses that were produced by sorafenib were not long-
lasting but it was most effective when given after the induction and consolidation phases 
of chemotherapy as well as during maintenance therapy and it increased the median 
event-free survival when compared to placebo. 
Midostaurin is the only tyrosine kinase inhibitor that has been approved by the 
FDA to treat patients with AML. The consensus among the literature in regards to 
midostaurin is that the drug is not an effective treatment of FLT3-ITD mutated AML 
when used alone. When midostaurin is combined with chemotherapy there was a drastic 
improvement in overall survival as well as a decrease in relapse rate and death. The 
therapeutic combination of standard induction and consolidation chemotherapy 
concurrently with midostaurin is a promising treatment for patients with FLT3-ITD 
mutated AML. Midostaurin and its metabolites can change the levels of drug in the 
patient’s system and when used as a single-agent, a mutation can arise that confers 
resistance to the drug. Trials that combined chemotherapy with midostaurin did not 
exhibit the drug resistance mechanism.  
Second-generation tyrosine kinase inhibitors have shown more targeted 
effectiveness in reducing the number of bone marrow blasts in addition to peripheral 
blood blasts. These tyrosine kinase inhibitors, such as quizartinib, have also shown toxic 
side effects including QT prolongation and myelosuppression. In addition, the potent 
targeted therapy of quizartinib towards FLT3-ITD mutated AML was problematic when 
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secondary acquired mutations occurred. Due to the targeted approach of quizartinib, it is 
unable to be effective once other mutations arise. Clinical trials involving crenolanib 
have shown that there is a clinical response but it is not enough to be used as a single-
agent. There are clinical trials currently occurring that are testing the efficacy of 
crenolanib in combination with chemotherapy.  
A consensus among all of the published literature is that resistance to therapeutics 
poses an important barrier to AML treatment options. One potential mechanism for 
avoiding resistance that was mentioned in the majority of the literature is that a 
combinatorial approach with chemotherapy and a tyrosine kinase inhibitor would be 
effective in preventing resistance mechanisms from occurring in patients with FLT3-ITD 
mutated AML. 
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CONCLUSION 
 
Significant advances have been made toward successful long-term treatment 
options for patients with FLT3-ITD mutated AML but there are still challenges and 
opportunities for improvement. The literature has shown that chemotherapy alone is an 
ineffective treatment option for patients with any type of AML. The addition of HSCT to 
chemotherapy was effective in reducing the risk of relapse in patients with the FLT3-ITD 
mutation. Unfortunately, this treatment was not sufficient to improve the overall five-year 
survival rate. In order to inhibit the activity of the FLT3-ITD mutation in AML and to 
sustain the inhibition, a combination of therapies should be utilized. It is important to 
continue to utilize targeted therapies because thus far chemotherapy has been ineffective 
in preventing relapse and lengthening the life of patients with FLT3-ITD AML.  
Single-agent trials found that although all of the FLT3 inhibitors evoked a clinical 
response, it was not long lasting. Improved results were seen when the FLT3 inhibitors 
were combined with standard chemotherapy and in some cases with HSCT as well. 
Although second-generation inhibitors have shown promise in their potent targeting 
toward FLT3-ITD mutated AML, it is problematic that patients develop resistance once 
secondary mutations arise. Additional novel therapeutics need to be developed to help 
strengthen the clinical response to tyrosine kinase inhibitors. They have been shown to 
successfully diminish the blast count in peripheral blood but have been less successful in 
reducing blasts in the bone marrow. By adding novel therapeutics that are developed to 
prevent drug resistance there will be an increase in patient survival.  
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Midostaurin is the first FLT3 inhibitor to be approved to treat patients with AML 
in combination with chemotherapy. In clinical trials, the effects were more apparent in 
patients with the FLT3-ITD mutation when compared to patients with wild-type FLT3. 
Midostaurin in addition to chemotherapy has been shown to significantly improve the 
overall survival for patients with FLT3-ITD mutated AML. This combination therapy has 
also been effective in preventing the drug resistance mechanisms that occurred when 
midostaurin was used as a single-agent. This is a positive step forward in the treatment of 
patients with FLT3-ITD AML.  
Further research needs to be conducted in trying different combinations of 
therapeutics to determine whether they are able to bypass mechanisms of resistance. The 
discovery of novel therapeutics that are created specifically to target common resistance 
mechanisms may also be helpful if added to therapeutic regimens. Further studies should 
be conducted to determine the best combination of therapeutics that avoids resistance and 
increases overall survival for patients with FLT3-ITD mutations 
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